Close Menu

This article has been updated with information and quotes from Myriad Genetics' Q2 earnings call. 

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its second quarter revenues in fiscal 2017 grew 2 percent, beating Wall Street expectations.

For the three months ended Dec. 31, the firm reported total revenues of $196.5 million, compared to $193.3 million in Q2 2016, and beating the consensus Wall Street estimate of $189.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.